Galapagos NV

GLPG

BE0003818359

Biotechnology & Medical Research

Real-time Euronext Amsterdam Other stock markets 09:59:51 2024-04-26 am EDT			5-day change	1st Jan Change
26.5 ^EUR	-0.23%		-2.65%	-28.47%

Apr. 08	Galapagos Showcases Innovative Approach in Hematological Cancer Care with Clinical and Translational Data Presentations at EBMT Congress 2024	CI
Mar. 28	Galapagos Continues to be 'Value Trap' With Unclear Growth Path, BofA Says	MT

Galapagos NV(ENXTAM:GLPG) dropped from S&P EUROPE 350 - Pharmaceuticals, Biotechnology & Life Sciences (Industry Group)

June 21, 2021 at 12:00 am EDT

Latest news about Galapagos NV

Galapagos Showcases Innovative Approach in Hematological Cancer Care with Clinical and Translational Data Presentations at EBMT Congress 2024	Apr. 08	CI
Galapagos Continues to be 'Value Trap' With Unclear Growth Path, BofA Says	Mar. 28	MT
BofA Securities Downgrades Galapagos to Underperform From Neutral, Says 'Stock Remains a Value Trap'; Adjusts Price Target to $31 From $41	Mar. 28	MT
Galapagos NV Announces Board Changes	Mar. 27	CI
Galapagos to Seek Acquisitions	Feb. 23	CI
Transcript : Galapagos NV, 2023 Earnings Call, Feb 23, 2024	Feb. 23
Frontier Medicines Corporation announced that it has received $80.000001 million in funding from Deerfield Management Company, L.P. Series C, DROIA nv, Galapagos NV, DCVC, MPM Asset Management, L.L.C., RA Capital Management, L.P. and other investors	Feb. 21	CI
Galapagos NV Reports Earnings Results for the Full Year Ended December 31, 2023	Feb. 21	CI
Galapagos NV to Present New Preliminary Translational Data at EBMT-EHA Annual Meeting 2024	Feb. 15	CI
Galapagos Completes Sale of Jyseleca Business to Alfasigma	Feb. 01	MT
Frontier Medicines Corporation announced that it expects to receive $99.999997 million in funding	Jan. 30	CI
Alfasigma S.p.A. completed the acquisition of Filgotinib business from Galapagos NV.	Jan. 30	CI
Galapagos NV Enters into Strategic Collaboration Agreement with Thermo Fisher Scientific, Inc. to Further Expand Its Decentralized CAR-T Manufacturing Network in the U.S	Jan. 05	CI
Galapagos Partners with Thermo Fisher for Manufacturing in US	Jan. 05	MT
Galapagos, Thermo Fisher Scientific to Establish Decentralized CAR-T Manufacturing Network	Jan. 04	MT
Galapagos, Thermo Fisher to Collaborate on Expanding Manufacturing of Cancer Drug	Jan. 04	DJ
Galapagos, BridGene Biosciences Partner to Develop New Medicines for Oncology Targets	Jan. 04	MT
Galapagos to Collaborate With BridGene to Discover, Develop New Medicines for Oncology Targets	Jan. 03	MT
BridGene Biosciences, Inc. Announces Strategic Collaboration and Licensing Agreement with Galapagos NV	Jan. 03	CI
Global markets live: HSBC, Baidu, Exxon Mobil, Geely, Tesla...	Jan. 02
Galapagos to Divest Jyseleca Business in Biotechnology Shift	Jan. 02	MT
Michele Manto to Join Alfasigma and Resigns from His Position as Chief Commercial Officer and Executive Committee Member At Galapagos	Jan. 02	CI
Galapagos Announces Start of PAPILIO-1 Phase 1/2 Multiple Myeloma Study of Point-Of-Care Manufactured BCMA CAR-T Candidate, GLPG5301	Dec. 21	CI
Galapagos Begins Clinical Trial for Cell Maturation Antigen on Patients with Refractory Multiple Myeloma	Dec. 20	MT
Galapagos Presents New Encouraging Clinical Data from the Ongoing Phase 1/2 CD19 CAR-T Studies with GLPG5201 and GLPG5101	Dec. 12	CI

Galapagos NV is a fully integrated biotechnology company focused on discovering, developing, and commercializing innovative medicines. The company is committed to improving patients' lives worldwide by targeting diseases with high unmet needs. Its R&D capabilities cover multiple drug modalities, including small molecules and cell therapies. Its portfolio comprises discovery through to commercialized programs in immunology, oncology, and other indications. Its first medicine for rheumatoid arthritis and ulcerative colitis is available in Europe and Japan.

Sector

Biotechnology & Medical Research

Calendar

2024-04-30 - Annual General Meeting

Related indices

BEL-20

More about the company

Income Statement Evolution

More financial data

Ratings for Galapagos NV

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

HOLD

Number of Analysts

Last Close Price

26.56 EUR

Average target price

38.43 EUR

Spread / Average Target

+44.69%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
GALAPAGOS NV	-28.47%	1.87B
IQVIA HOLDINGS INC.	+1.61%	42.59B
MODERNA, INC.	+7.85%	40.65B
LONZA GROUP AG	+48.32%	40.57B
CELLTRION, INC.	-11.96%	26.77B
ICON PUBLIC LIMITED COMPANY	+8.50%	24.81B
ALNYLAM PHARMACEUTICALS, INC.	-24.72%	18.17B
MEDPACE HOLDINGS, INC.	+27.98%	12.05B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-2.82%	11.7B
UNITED THERAPEUTICS CORPORATION	+7.47%	11.1B

Other Biotechnology & Medical Research

Galapagos NV

Equities

GLPG

BE0003818359

Biotechnology & Medical Research

Galapagos NV(ENXTAM:GLPG) dropped from S&P EUROPE 350 - Pharmaceuticals, Biotechnology & Life Sciences (Industry Group)

Latest news about Galapagos NV

Chart Galapagos NV

Company Profile

Income Statement Evolution

Ratings for Galapagos NV

Analysts' Consensus

EPS Revisions

Quarterly earnings - Rate of surprise

Sector Other Biotechnology & Medical Research